Okamoto et al. found that 50% of ovarian cancer patients were IDO1-positive and that the overall survival was 11 months in patients with diffuse distribution compared with 41 months survival in patients with sporadic distribution [10]. Here, IDO1 is linked to ovarian carcinoma.